Zhang, Baoyuan
Li, Ning
Gao, Jiaming
Zhao, Yuxi
Jiang, Jun
Xie, Shuang
Zhang, Cuiping
Zhang, Qingyu
Liu, Leo
Wang, Zaiqi
Ji, Dongmei
Wu, Lingying
Ren, Ruibao
Funding for this research was provided by:
Key Project of National Natural Science Foundation of China (82230088)
Shanghai Science and Technology Development Foundation (20Z11900200)
Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research (2019CXJQ01)
Article History
Received: 31 July 2023
Accepted: 3 February 2024
First Online: 19 February 2024
Change Date: 16 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13046-024-03033-8
Declarations
:
: The clinical trial in this study was conducted following the Declaration of Helsinki and approved by the institutional review board of Cancer Hospital Chinese Academy of Medical Sciences (Beijing, China) according to Good Clinical Practices and applicable laws and regulations. All methods were performed in accordance with the relevant guidelines and regulations. All patients provided written informed consent.All animal studies were performed according to the protocols approved by the ethics committee of Shanghai Jiao Tong University School of Medicine (SJTU-SM) and conducted in accordance with AAALAC guidelines.
: All authors revised and approved the manuscript.
: J.J., S.X., L.L., and Z.Q.W. are employees of InxMed. The other authors declare no conflict of interest.